The President’s Malaria Initiative (PMI) is a U.S. government program designed to reduce malaria deaths by half in target countries in sub-Saharan Africa where infection rates are particularly high. It was announced on June 30, 2005 by U.S. President George W. Bush, who pledged, in cooperation with U.S. private companies, to increase U.S. funding for malaria in sub-Saharan Africa by more than U.S.$1.2 billion over five years (fiscal 2006 to fiscal 2010).
In partnership with African governments, PMI has developed a number of plans to control malaria to date. PMI has been driven by the U.S. Agency for International Development (USAID) with participation from CDC. Many NGOs and other organizations are also taking part or lending support: WHO, the World Bank, Roll Back Malaria (RBM), UNICEF, the International Red Cross Society, and the Global Fund to Fight AIDS, TB (tuberculosis), and Malaria. PMI currently has the following four programs targeting people at high risk of infection (pregnant women and children under five) in 19 countries and territories in sub-Saharan Africa and the Greater Mekong Subregion:
- long-lasting insecticide-treated nets
- artemisinin-based combination therapies (ACTs)
- preventive treatment for pregnant women
- indoor residual spraying with approved insecticides
WHO launched the Global Malaria Programme (GMP） to control malaria. GMP is staffed by people who help to prevent, control, and study malaria as well as set evidence-based policies and guidelines for monitoring malaria in cooperation with experts. GMP has, on its own initiative, collected data on malaria control from all over the world.
Major GMP partners include the African Leaders Malaria Alliance, the Global Fund to Fight AIDS, TB and Malaria, the Foundation for Innovative New Diagnostics, Imperial College London and numerous other public organizations, universities and similar groups. GMP also receives support from the Bill & Melinda Gates Foundation, the Canadian International Development Agency, the governments of Australia, Norway, Japan, the Russian Federation and the United Kingdom, and the U.S. Agency for International Development.
WHO adopted a new strategy in May 2015, "The WHO Global Technical Strategy for Malaria 2016-2030",
to achieve the following:
- reducing malaria case incidence by at least 90% by 2030
- reducing malaria mortality rates by at least 90% by 2030
- eliminating malaria in at least 35 countries by 2030
- preventing a resurgence of malaria in all countries that are malaria-free
The Medicine for Malaria Venture (MMV) is an NPO founded in 1999 in Switzerland through a government–private partnership. MMV contributes to the control of malaria through the development and distribution of effective and accessible antimalarial drugs.
Eisai, in cooperation with multiple research institutes, researches and develops drugs and vaccines for combating malaria and other NTDs.